XML 141 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 19, 2022
Feb. 15, 2022
Nov. 27, 2018
Aug. 15, 2018
Mar. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reimbursement or royalty paid             $ 0
Contingent payments due           $ 0  
Global and BioLife Sciences [Member]              
Sale of royalty, percentage   20.00%          
Equity Method Investment, Ownership Percentage   20.00%          
Royalty Agreement [Member]              
Royalty, percentage       50.00%      
Royalty Agreement [Member] | Chemia Corporation [Member]              
Royalty, percentage       50.00%      
Sale of royalty, percentage     5.00%        
License Agreement [Member]              
Sale of royalty, percentage 5.50%            
Development cost, percent 50.00%            
Costs Incurred, Development Costs $ 1,250,000            
Development Costs, Period Cost         $ 152,000 200,000 $ 0
Contingent legal fees           $ 0